Seres Therapeutics (NASDAQ:MCRB) Raised to Hold at StockNews.com

StockNews.com upgraded shares of Seres Therapeutics (NASDAQ:MCRB) from a sell rating to a hold rating in a report issued on Tuesday morning.

A number of other analysts also recently commented on MCRB. Oppenheimer reissued a market perform rating on shares of Seres Therapeutics in a report on Friday, June 7th. Chardan Capital dropped their price objective on shares of Seres Therapeutics from $8.00 to $6.00 and set a buy rating for the company in a research report on Wednesday, May 8th. Finally, Canaccord Genuity Group decreased their price objective on shares of Seres Therapeutics from $15.00 to $10.00 and set a buy rating for the company in a report on Friday, June 7th.

Seres Therapeutics Trading Up 9.4 %

MCRB opened at $1.07 on Tuesday. Seres Therapeutics has a 12 month low of $0.54 and a 12 month high of $5.29. The stock has a 50-day moving average of $0.87 and a 200 day moving average of $0.96. The firm has a market cap of $162.05 million, a P/E ratio of -1.78 and a beta of 1.98.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.09. On average, research analysts forecast that Seres Therapeutics will post -1.03 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Seres Therapeutics

Several large investors have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Seres Therapeutics in the first quarter worth $39,000. Tower Research Capital LLC TRC lifted its stake in Seres Therapeutics by 668.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 38,091 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 33,135 shares during the period. SG Americas Securities LLC acquired a new position in Seres Therapeutics in the fourth quarter valued at approximately $73,000. Virtu Financial LLC acquired a new position in Seres Therapeutics in the first quarter valued at approximately $73,000. Finally, Pennant Investors LP bought a new stake in shares of Seres Therapeutics during the fourth quarter valued at approximately $409,000. Institutional investors and hedge funds own 59.34% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.